Seoul St. Mary’s Hospital, Hormone therapy is required to protect bone-healthy after hematopoietic stem cell transplantation.

Hormone therapy is required to protect bone-healthy after hematopoietic stem cell transplantation.Seoul St. Mary's Hospital Endocrinology Department Professor Moo-il Kang, Hematology Department Professor Jong-wook Lee team Analysis of the effect of hormone therapy in patients with ovarian failure after hematopoietic stem cell transplantation Hormone therapy group significantly increases bone density compared to non-therapeutic group Published in the September issue of the American Journal of Clinical Endocrinology and Metabolism The Catholic University of Korea, Seoul St. Mary's Hospital, Professor Moo-il Kang (co-corresponding author), Professor Jong-wook Lee (co-corresponding author) of the Department of Hematology, Professor Jeong-Hoon Ha (co-first author) of the Department of Endocrinology, and Professor Seong-Soo Park of the Department of Hematology (co-first author) team analyzed the effectiveness of hormone therapy on 234 patients under the age of 40 who had premature ovarian failure after receiving hematopoietic stem cell transplants at Seoul St. Mary's Hospital from 2009 to 2016, and found that the group that received active treatment early showed excellent improvement in bone density. The research team divided the target patients into a hormone-treated group (170 people) and a non-treated group (64 people), and measured the bone density of the spine and femur for 24 months, and it was confirmed that the lumbar bone density of the hormone-treated group in particular increased significantly. When hormone therapy was performed, the vertebrae density increased the most, and after two years of hormone therapy, the vertebrae density increased by more than 5.42% before treatment. Usually, women experience drastic physical and emotional changes when their ovaries deteriorate as they age, reducing the secretion of female hormones. However, premature ovarian failure occurs frequently during the treatment when hematopoietic stem cell transplantation is performed. This means that even at a young age, you are more likely to be exposed to various diseases caused by decreased female hormones. From common menopause symptoms such as facial flushing, sleep disorders, depression, and muscle pain, to various symptoms related to the quality of life, such as sexual dysfunction, cognitive impairment, and increased risk of fractures. In particular, the reduction in bone density after transplantation increases the risk of fractures, adversely affects the quality of life when fractures occur, and also increases the mortality rate due to the fracture itself, so management is essential. The results of this study were published online prior to publication in the September 2020 issue of the Journal of Clinical Endocrinology & Metabolism. Patients who received hormone therapy (marked with HRT (+)) had a higher increase in spinal or femur bone density than those who did not (marked with HRT (-)). In particular, in the case of vertebral bone density, the increase in bone density was significantly confirmed when hormone treatment was performed.